Quantcast
Higher BMI Found To Increase Risk Of Several Types Of Cancer

Higher BMI Found To Increase Risk Of Several Types Of Cancer

redOrbit Staff & Wire Reports - Your Universe Online Obesity increases a person’s risk of developing 10 of the most common forms of cancer, and is believed to cause an estimated 12,000 additional cases of the disease each year, experts...

Latest liver cancer Stories

2014-08-14 08:29:11

CEO to Present Significance of Announced Clinical Trial Results for Lead Drug G-202 Treating Hepatocellular Carcinoma (HCC) Patients to Wall Street Audience SAN ANTONIO, Aug. 14, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. The conference will be held September 8-10, 2014 at the New York Palace Hotel in...

2014-08-05 08:33:58

POINT ROBERTS, Wash. and NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Investorideas.com, a global news source covering leading sectors including biotech, issues an exclusive Q&A interview with Dr. Craig Dionne, PhD, GenSpera's (OTCQB: GNSZ) CEO. Dr. Dionne discusses the company's lead drug G-202 and how they have taken a powerful toxin named thapsigargin to selectively target and kill cancer cells. He also shares insight into the key points that make them different from competitive...

2014-07-29 23:13:49

San Antonio researcher leads national study that identified a combination of pills that cures 9 of 10 hepatitis C patients. San Antonio, TX (PRWEB) July 29, 2014 Researchers from The University of Texas Health Science Center at San Antonio, the Texas Liver Institute and other institutions have identified a combination of pills that cures 9 of 10 hepatitis C patients. The combination of the drugs sofosbuvir and simeprevir, with or without ribavirin, cured 93 percent of patients in 12...

2014-07-28 13:22:50

Cancer Research UK Cancer Research UK scientists at Barts Cancer Institute have found that targeting a molecule in blood vessels can make cancer therapy significantly more effective, according to research published in Nature today (Sunday). The team at Barts Cancer Institute, part of Queen Mary University of London, have found that a molecule, called focal adhesion kinase (FAK), signals the body to repair itself after chemotherapy or radiotherapy, which kill cancer cells by damaging...

2014-07-28 08:29:13

Latest Data Sweep from a 285 Patient Subgroup Shows An Impressive 57% Improvement in Overall Survival LAWRENCEVILLE, N.J., July 28, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as...

2014-07-22 08:31:31

"These positive results enable management to remain optimistic about our ambitious G-202 clinical development program"- Dr. Craig Dionne, CEO SAN ANTONIO, July 22, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) presentation of the G-202 hepatocellular carcinoma (HCC) clinical trial data is now available for download for media and...

2014-07-15 08:28:28

Eighty Percent of Patients Treated with G-202 had No Tumor Growth at Two Months SAN ANTONIO, July 15, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the APPLE 2014 presentation. Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in hepatocellular carcinoma (HCC) patients, presented the HCC clinical trial update for G-202 at the 5(th) Asia-Pacific Primary Liver...

2014-07-14 12:27:28

HYDERABAD, India, July 14, 2014 /PRNewswire/ -- Clinicians at a leading cancer center in India have become the first in the country to commence advanced lung, liver and brain radiotherapy treatments using an upgraded Clinac® medical linear accelerator from Varian Medical Systems (NYSE: VAR). The accelerator has been enhanced with High Intensity Mode dose delivery capability, which is allowing doctors at Yashoda Cancer Institute to shorten treatment times and deliver stereotactic body...

2014-07-10 08:27:12

Patient was previously enrolled in Can-Fite's Phase I/II liver cancer study and has survived for about 5-years using the Company's cancer drug; The global liver cancer drug market is expected to exceed $2 billion by 2015 PETACH TIKVA, Israel, July 10, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli...

2014-07-09 11:33:39

The Mount Sinai Hospital / Mount Sinai School of Medicine Two genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, according to a research published in the July issue of the journal Nature. A team led by the Icahn School of Medicine at Mount Sinai and Harvard Medical School has discovered a link between the presence of two mutant proteins IDH1 and IDH2 and cancer. Past studies have found IDH...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.